Detalhe da pesquisa
1.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
2.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414012
3.
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
Blood
; 134(15): 1247-1256, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31395601
4.
Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.
Transfusion
; 59(5): 1773-1780, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729531
5.
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Blood Adv
; 6(1): 37-45, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34649272
6.
A clinical perspective on plasma cell leukemia; current status and future directions.
Blood Cancer J
; 11(2): 23, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563906
7.
Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
Cancer J
; 27(2): 112-118, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33750070
8.
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Transplant Cell Ther
; 27(1): 57.e1-57.e8, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32980545
9.
90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.
Bone Marrow Transplant
; 56(1): 202-209, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32710011
10.
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.
Blood Adv
; 7(23): 7235-7238, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844282